	US 12,006,368 B2
	Anti-frizzled antibodies and methods of use
Yang Li, Mountain View, CA (US); Tom Zhiye Yuan, Union City, CA (US); Aaron Ken Sato, Burlingame, CA (US); Wen-Chen Yeh, Belmont, CA (US); Chenggang Lu, South San Francisco, CA (US); Parthasarathy Sampathkumar, South San Francisco, CA (US); and Claudia Yvonne Janda, South San Francisco, CA (US)
Assigned to Surrozen Operating, Inc., South San Francisco, CA (US)
Appl. No. 16/954,482
Filed by Surrozen Operating, Inc., South San Francisco, CA (US)
PCT Filed Dec. 19, 2018, PCT No. PCT/US2018/066618 § 371(c)(1), (2) Date Jun. 16, 2020, PCT Pub. No. WO2019/126399, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/680,508, filed on Jun. 4, 2018.
Claims priority of provisional application 62/607,877, filed on Dec. 19, 2017.
Prior Publication US 2021/0087280 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2863 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)]

8 Claims

1. An isolated antibody, or an antigen-binding fragment thereof, that binds to Frizzled 5 and Frizzled 8, comprising:

a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3 sequences set forth as SEQ ID NOs: 218, 410, and 861, respectively; and

a light chain variable region comprising CDRL1, CDRL2 and CDRL3 sequences set forth as SEQ ID NOs: 996, 1071, and 1264, respectively.